Search clinical trials for: B-cells

Total 2257 results

National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Hoffmann-La Roche

Terminated

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

Romania
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche

Terminated

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United Kingdom
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19 Positive Malignant B-cell Leukemia and Lymphoma

China
Peking University Cancer Hospital & Institute

Unknown

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Peking University Cancer Hospital & Institute

Unknown

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Centre Henri Becquerel

Completed

Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma (SARCOPENIE)

Diffuse Large B Cell Lymphoma | Grade IIIB Follicular Lymphoma

France
University Hospital, Bordeaux
Bayer

Completed

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) (ZEVALLO)

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

France
German CLL Study Group
University of Cologne; MedacSchering Onkologie

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

B-cell Chronic Lymphocytic Leukemia

Germany
University Hospital, Bordeaux

Completed

Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma (REV-LEG)

Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)

France
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma

Lymphoma

United States
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
CHU de Reims

Unknown

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)

Indolent Cutaneous B Cell Lymphomas

France
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Northwell Health

Terminated

Hydroxychloroquine in Untreated B-CLL Patients

B-Cell Chronic Lymphocytic Leukemia

United States
University of Pennsylvania
GlaxoSmithKline

Completed

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Neumedicines Inc.

Unknown

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Lymphoma, Large B-Cell, Diffuse (DLBCL)
Genzyme, a Sanofi Company

Completed

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

B Cell Chronic Lymphocytic Leukemia

United States
Asan Medical Center

Unknown

Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Diffuse Large B-cell Lymphoma

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia

Leukemia

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia

Leukemia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Celgene Corporation

Terminated

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc

Completed

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS

United States
National University Hospital, Singapore
National University of Singapore

Unknown

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Non-Hodgkin's Lymphoma | B-Cell Chronic Lymphocytic Leukemia

Singapore
Centro di Riferimento Oncologico - Aviano

Unknown

Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma

Lymphoma

Italy
University of North Carolina, Chapel Hill

Withdrawn

Walnut Oral Immunotherapy for Tree Nut Allergy (WOIT)

Nut Hypersensitivities
Pusan National University Hospital

Unknown

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

Diffuse Large B-cell Lymphoma
Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
Czech Lymphoma Study Group

Unknown

CNS Prophylaxis in Diffuse Large B-cell Lymphoma (CLSG-CNS-001)

Diffuse Large B-cell Lymphoma

Czech Republic
MedDerm Associates

Terminated

Study to Evaluate Broadlumab vs Placebo and Ustekinumab (AMAGINE-3)

Psoriasis

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Hoffmann-La Roche

Completed

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular NHL Grade 3b

Hong Kong, Thailand, Sweden, Taiwan, Mexico, Austria, Serbia, China, Czech Republic, Australia, Malaysia, Croatia, Israel, South Africa, Bosnia and Herzegovina, Brazil, Bulgaria, Estonia, Latvia, Macedonia, The Former Yugoslav... and more
The Lymphoma Academic Research Organisation
Pfizer

Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Diffuse Large B-Cell Lymphoma

France, Belgium
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial

Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia

Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia

Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia

Leukemia

United States
Sinocelltech Ltd.

Unknown

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Lymphoma | Leukemia

United States
Ohio State University Comprehensive Cancer Center
Amgen

Completed

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Hematopoietic/Lymphoid Cancer | Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

Lymphoma, Non-Hodgkin

France
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

Systemic Lupus Erythematosus

Japan
University Hospital, Caen

Unknown

CyBeR Association in Relapsed/Refractory DLBCL (CyBeR-Lymph)

Diffuse Large B Cell Lymphoma
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China

Search clinical trials for: B-cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations